{
    "clinical_study": {
        "@rank": "6401", 
        "arm_group": [
            {
                "arm_group_label": "Rep + NPH", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Premixed insulin/NPH", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia. The aim of this trial is to compare oral anti-diabetic drug\n      (OAD) combined with insulin vs. insulin alone in subjects with type 2 diabetes not\n      adequately controlled on the current OAD therapy."
        }, 
        "brief_title": "Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes", 
        "completion_date": {
            "#text": "April 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HbA1c between 7.5 % and 13.0% (both inclusive)\n\n          -  Fasting C-peptide above or equal to 0.33 nmol/l\n\n          -  BMI (Body Mass Index) between 25 and 32 kg/m2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Medical history of treatment with insulin within the last 6 months\n\n          -  Impaired renal function, defined as serum creatinine above to 1.7 mg/dl (150 \u00b5mol/l)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "159", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720303", 
            "org_study_id": "AGEE-3020"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rep + NPH", 
                "description": "2 mg (tablets) before each main meal", 
                "intervention_name": "repaglinide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Rep + NPH", 
                "description": "Injection s.c. (under the skin) at bedtime", 
                "intervention_name": "isophane human insulin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Premixed insulin/NPH", 
                "description": "Injection s.c. (under the skin) twice daily", 
                "intervention_name": "insulin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Repaglinide", 
                "Insulin", 
                "Insulin, NPH"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 31, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200040"
                }
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-centre, Open, Randomised, Parallel, Controlled Trial to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime Insulin With Insulin Alone in Type 2 Diabetic Subjects Inadequately Controlled With Sulphonylurea \u00b1 Biguanide Therapy", 
        "overall_official": {
            "affiliation": "Novo Nordisk (China) Pharmaceuticals Co., Ltd", 
            "last_name": "Qian Hongyu", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720303"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in FBG (Fasting Blood Glucose)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Change in body weight", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}